Literature DB >> 32831293

GLS1-mediated glutaminolysis unbridled by MALT1 protease promotes psoriasis pathogenesis.

Xichun Xia1, Guangchao Cao2,3, Guodong Sun4, Leqing Zhu1, Yixia Tian2, Yueqi Song1, Chengbin Guo1, Xiao Wang1, Jingxiang Zhong5, Wei Zhou1, Peng Li1, Hua Zhang2, Jianlei Hao2,3, Zhizhong Li4,6, Liehua Deng7, Zhinan Yin2,3, Yunfei Gao2,3.   

Abstract

Psoriasis is a severe disease associated with the disturbance of metabolism and inflammation, but the molecular mechanisms underlying these aspects of psoriasis pathology are poorly understood. Here, we report that glutaminase 1-mediated (GLS1-mediated) glutaminolysis was aberrantly activated in patients with psoriasis and in psoriasis-like mouse models, which promoted Th17 and γδ T17 (IL-17A-producing γδ T) cell differentiation through enhancement of histone H3 acetylation of the Il17a promoter, thereby contributing to the immune imbalance and development of psoriasis. We further demonstrate that mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) protease was constitutively active in psoriatic CD4+ and γδ T cells, thereby supporting GLS1 expression by stabilizing c-Jun, which directly binds to the GLS1 promoter region. Blocking the activity of either GLS1 or MALT1 protease resolved Th17 and γδ T17 cell differentiation and epidermal hyperplasia in the psoriasis-like mouse models. Finally, IL-17A enhanced GLS1 expression via the MALT1/cJun pathway in keratinocytes, resulting in hyperproliferation of and chemokine production by keratinocytes. Our findings identify the role of the MALT1/cJun/GLS1/glutaminolysis/H3 acetylation/T17 axis in psoriasis pathogenesis and reveal potential therapeutic targets for this disease.

Entities:  

Keywords:  Amino acid metabolism; Autoimmunity; Dermatology; T cells

Year:  2020        PMID: 32831293      PMCID: PMC7524468          DOI: 10.1172/JCI129269

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  62 in total

1.  Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism.

Authors:  Marc O Johnson; Melissa M Wolf; Matthew Z Madden; Gabriela Andrejeva; Ayaka Sugiura; Diana C Contreras; Damian Maseda; Maria V Liberti; Katelyn Paz; Rigel J Kishton; Matthew E Johnson; Aguirre A de Cubas; Pingsheng Wu; Gongbo Li; Yongliang Zhang; Dawn C Newcomb; Andrew D Wells; Nicholas P Restifo; W Kimryn Rathmell; Jason W Locasale; Marco L Davila; Bruce R Blazar; Jeffrey C Rathmell
Journal:  Cell       Date:  2018-11-01       Impact factor: 41.582

2.  Ustekinumab for chronic plaque psoriasis.

Authors:  Brenda L Bartlett; Stephen K Tyring
Journal:  Lancet       Date:  2008-05-17       Impact factor: 79.321

3.  Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.

Authors:  K Papp; D Thaçi; K Reich; E Riedl; R G Langley; J G Krueger; A B Gottlieb; H Nakagawa; E P Bowman; A Mehta; Q Li; Y Zhou; R Shames
Journal:  Br J Dermatol       Date:  2015-10-15       Impact factor: 9.302

4.  Abnormal histone modifications in PBMCs from patients with psoriasis vulgaris.

Authors:  Peng Zhang; Yuwen Su; Ming Zhao; Wei Huang; Qianjin Lu
Journal:  Eur J Dermatol       Date:  2011 Jul-Aug       Impact factor: 3.328

5.  Gain-of-Function Mutation of Card14 Leads to Spontaneous Psoriasis-like Skin Inflammation through Enhanced Keratinocyte Response to IL-17A.

Authors:  Mingchao Wang; Shanshan Zhang; Guoxing Zheng; Junjiu Huang; Zhou Songyang; Xueqiang Zhao; Xin Lin
Journal:  Immunity       Date:  2018-07-03       Impact factor: 31.745

Review 6.  Regulation and function of mTOR signalling in T cell fate decisions.

Authors:  Hongbo Chi
Journal:  Nat Rev Immunol       Date:  2012-04-20       Impact factor: 53.106

7.  TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression.

Authors:  Hou-Pu Liu; Anthony T Cao; Ting Feng; Qingjie Li; Wenbo Zhang; Suxia Yao; Sara M Dann; Charles O Elson; Yingzi Cong
Journal:  Eur J Immunol       Date:  2015-02-11       Impact factor: 5.532

8.  Exploration of candidate biomarkers for human psoriasis based on gas chromatography-mass spectrometry serum metabolomics.

Authors:  H Kang; X Li; Q Zhou; C Quan; F Xue; J Zheng; Y Yu
Journal:  Br J Dermatol       Date:  2016-12-27       Impact factor: 9.302

9.  Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells.

Authors:  Thomas Duhen; Rebekka Geiger; David Jarrossay; Antonio Lanzavecchia; Federica Sallusto
Journal:  Nat Immunol       Date:  2009-07-05       Impact factor: 25.606

10.  The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy.

Authors:  Michael J Lukey; Kai Su Greene; Jon W Erickson; Kristin F Wilson; Richard A Cerione
Journal:  Nat Commun       Date:  2016-04-18       Impact factor: 14.919

View more
  12 in total

1.  Differential metabolic requirement governed by transcription factor c-Maf dictates innate γδT17 effector functionality in mice and humans.

Authors:  Xu Chen; Yihua Cai; Xiaoling Hu; Chuanlin Ding; Liqing He; Xiang Zhang; Fuxiang Chen; Jun Yan
Journal:  Sci Adv       Date:  2022-05-25       Impact factor: 14.957

2.  Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation.

Authors:  Qiang Yu; Honghu Tu; Xueyi Yin; Chang Peng; Chuanyun Dou; Wenhua Yang; Wenbiao Wu; Xiaotong Guan; Jia Li; Hexin Yan; Yi Zang; Haowen Jiang; Qiang Xia
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

Review 3.  Advances in the pathogenesis of psoriasis: from keratinocyte perspective.

Authors:  Xue Zhou; Youdong Chen; Lian Cui; Yuling Shi; Chunyuan Guo
Journal:  Cell Death Dis       Date:  2022-01-24       Impact factor: 9.685

4.  Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients.

Authors:  Zhigang Wu; Yingyan Bi
Journal:  J Clin Lab Anal       Date:  2022-01-08       Impact factor: 2.352

5.  Pharmacological Inhibition of Glutaminase 1 Normalized the Metabolic State and CD4+ T Cell Response in Sjogren's Syndrome.

Authors:  Jiayao Fu; Yiping Pu; Baoli Wang; Hui Li; Xiujuan Yang; Lisong Xie; Huan Shi; Zhijun Wang; Junhao Yin; Tianle Zhan; Yanxiong Shao; Changyu Chen; Qi Luo; Jiabao Xu; Zirui Zong; Xindi Wei; Wanwen Xiao; Chuangqi Yu; Lingyan Zheng
Journal:  J Immunol Res       Date:  2022-02-15       Impact factor: 4.818

Review 6.  The Paracaspase MALT1 in Cancer.

Authors:  Beatriz Gomez Solsona; Anja Schmitt; Klaus Schulze-Osthoff; Stephan Hailfinger
Journal:  Biomedicines       Date:  2022-02-01

Review 7.  Metabolic regulation of T cell development.

Authors:  Mengdi Zhang; Xiaoxi Lin; Zhou Yang; Xia Li; Zhiguang Zhou; Paul E Love; Jiaqi Huang; Bin Zhao
Journal:  Front Immunol       Date:  2022-07-25       Impact factor: 8.786

8.  MALT1 regulates Th2 and Th17 differentiation via NF-κB and JNK pathways, as well as correlates with disease activity and treatment outcome in rheumatoid arthritis.

Authors:  Qiubo Wang; Yapeng Wang; Qingyang Liu; Ying Chu; Rui Mi; Fengying Jiang; Jingjing Zhao; Kelong Hu; Ran Luo; Yufeng Feng; Harrison Lee; Dong Zhou; Jingyi Mi; Ruoyu Deng
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

9.  MALT1 serves as a biomarker for estimating disease risk of lupus nephritis: a prospective case-control study.

Authors:  Min Wang; Li Huang; Liping Peng; Yameng Yang; Jing Mao; Ning Zhu; Bin Wu
Journal:  Ann Transl Med       Date:  2022-08

Review 10.  The Complex Integration of T-cell Metabolism and Immunotherapy.

Authors:  Matthew Z Madden; Jeffrey C Rathmell
Journal:  Cancer Discov       Date:  2021-04-01       Impact factor: 39.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.